Management and Screening in Neurofibromatosis Types 1 and 2

Uusitalo E, Leppävirta J, Koffert A, Suominen S, Vahtera J, Vahlberg T, et al. Incidence and mortality of neurofibromatosis: a total population study in Finland. J Invest Dermatol. 2015;135(3):904–6. https://doi.org/10.1038/jid.2014.465. Hirbe AC, Gutmann DH. Neurofibromatosis type 1: a multidisciplinary approach to care. Lancet Neurol. 2014;13:834–43. Elefteriou F, Kolanczyk M, Schindeler A, Viskochil DH, Hock JM, Schorry EK, et al. Skeletal abnormalities in neurofibromatosis type 1: approaches to therapeutic options. Am J Med Genet A. 2009;149A:2327–38. National Institutes of Health Consensus Development Conference Statement: neurofibromatosis. Bethesda, Md., USA, July 13-15, 1987. Neurofibromatosis. 1988;1(3):172–8. Lehtonen A, Howie E, Trump D, Huson SM. Behaviour in children with neurofibromatosis type 1: cognition, executive function, attention, emotion, and social competence. Dev Med Child Neurol. 2013;55:111–25. Morris SM, Acosta MT, Garg S, Green J, Huson S, Legius E, et al. Disease burden and symptom structure of autism in neurofibromatosis type 1: a study of the International NF1-ASD Consortium Team (INFACT). JAMA Psychiatry. 2016;73:1276–84. Plasschaert E, Descheemaeker MJ, Van Eylen L, Noens I, Steyaert J, Legius E. Prevalence of autism spectrum disorder symptoms in children with neurofibromatosis type 1. Am J Med Genet B Neuropsychiatr Genet. 2015;168B:72–80. Descheemaeker MJ, Plasschaert E, Frijns JP, Legius E. Neuropsychological profile in adults with neurofibromatosis type 1 compared to a control group. J Intellect Disabil Res. 2013;57:874–86. Afridi SK, Leschziner GD, Ferner RE. Prevalence and clinical presentation of headache in a National Neurofibromatosis 1 Service and impact on quality of life. Am J Med Genet A. 2015;167A:2282–5. Evans DG, Baser ME, McGaughran J, Sharif S, Howard E, Moran A. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet. 2002;39(5):311–4. • Howell SJ, Hockenhull K, Salih Z, Evans DG. Increased risk of breast cancer in neurofibromatosis type 1: current insights. Breast Cancer (Dove Med Press). 2017;9:531–6 Useful evidence summary of breast cancer risk in women with NF1. Wang X, Levin AM, Smolinski SE, Vigneau FD, Levin NK, Tainsky MA. Breast cancer and other neoplasms in women with neurofibromatosis type 1: a retrospective review of cases in the Detroit metropolitan area. Am J Med Genet A. 2012;158A:3061–4. Madanikia SA, Bergner A, Ye X, Blakeley JO. Increased risk of breast cancer in women with NF1. Am J Med Genet A. 2012;158A:3056–60. Sabbagh A, Pasmant E, Laurendeau I, Parfait B, Barbarot S, Guillot B, et al. members of the NF France Network. Unravelling the genetic basis of variable clinical expression in neurofibromatosis 1. Hum Mol Genet. 2009;18(15):2768–78. https://doi.org/10.1093/hmg/ddp212. García-Romero MT, Parkin P, Lara-Corrales I. Mosaic Neurofibromatosis type 1: a systematic review. Pediatr Dermatol. 2016;33(1):9–17. https://doi.org/10.1111/pde.12673. De Raedt T, Brems H, Wolkenstein P, Vidaud D, Pilotti S, Perrone F, et al. Elevated risk for MPNST in NF1 microdeletion patients. Am J Hum Genet. 2003;72:1288–92. Pasmant E, Sabbagh A, Spurlock G, Laurendeau I, Grillo E, Hamel MJ, et al. NF1 microdeletions in neurofibromatosis type 1: from genotype to phenotype. Hum Mutat. 2010;31(6):E1506–18. https://doi.org/10.1002/humu.21271. De Luca A, Bottillo I, Dasdia MC, Morella A, Lanari V, Bernardini L, et al. Deletions of NF1 gene and exons detected by multiplex ligation-dependent probe amplification. J Med Genet. 2007;44(12):800–8. Koczkowska M, Chen Y, Callens T, Gomes A, Sharp A, Johnson S, et al. Genotype-phenotype correlation in NF1: evidence for a more severe phenotype associated with missense mutations affecting NF1 codons 844-848. Am J Hum Genet. 2018;102(1):69–87. https://doi.org/10.1016/j.ajhg.2017.12.001. Upadhyaya M, Huson SM, Davies M, Thomas N, Chuzhanova N, Giovannini S, et al. An absence of cutaneous neurofibromas associated with a 3-bp inframe deletion in exon 17 of the NF1 gene (c.2970-2972 delAAT): evidence of a clinically significant NF1 genotype-phenotype correlation. Am J Hum Genet. 2007;80(1):140–51. Rojnueangnit K, Xie J, Gomes A, Sharp A, Callens T, Chen Y, et al. High incidence of Noonan syndrome features including short stature and pulmonic stenosis in patients carrying NF1 missense mutations affecting p.Arg1809: genotype-phenotype correlation. Hum Mutat. 2015;36(11):1052–63. https://doi.org/10.1002/humu.22832. Pinna V, Lanari V, Daniele P, Consoli F, Agolini E, Margiotti K, et al. Arg1809Cys substitution in neurofibromin is associated with a distinctive NF1 phenotype without neurofibromas. Eur J Hum Genet. 2015;23:1068–71. Frayling IM, Mautner VF, van Minkelen R, Kallionpaa RA, Aktaş S, Baralle D, et al. Breast cancer risk in neurofibromatosis type 1 is a function of the type of NF1 gene mutation: a new genotype-phenotype correlation. J Med Genet. 2018:209–19. https://doi.org/10.1136/jmedgenet-2018-105599. De Luca A, Bottillo I, Sarkozy A, Carta C, Neri C, Bellacchio E, et al. NF1 gene mutations represent the major molecular event underlying neurofibromatosis-Noonan syndrome. Am J Hum Genet. 2005;77(6):1092–101. de Blank PMK, Fisher MJ, Liu GT, Gutmann DH, Listernick R, Ferner RE, et al. Optic pathway gliomas in neurofibromatosis type 1: an update: surveillance, treatment indications, and biomarkers of vision. J Neuroophthalmol. 2017;37(Suppl 1):S23–32. https://doi.org/10.1097/WNO.0000000000000550. Ferner RE, Golding JF, Smith M, Calonje E, Jan W, Sanjayanathan V, et al. [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study. Ann Oncol. 2008;19(2):390–4. Dunn GP, Spiliopoulos K, Plotkin SR, Hornicek FJ, Harmon DC, Delaney TF, et al. Role of resection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis type 1. J Neurosurg. 2013;118(1):142–8. https://doi.org/10.3171/2012.9.JNS101610. Karajannis MA, Ferner RE. Neurofibromatosis-related tumors: emerging biology and therapies. Curr Opin Pediatr. 2015;27(1):26–33. https://doi.org/10.1097/MOP.0000000000000169. • Blakeley JO, Plotkin SR. Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis. Neuro-Oncology. 2016;18(5):624–38. https://doi.org/10.1093/neuonc/nov200 Review of the current state of research into novel and targeted therapies in NF1 and NF2. Dombi E, Baldwin A, Marcus LJ, Fisher MJ, Weiss B, Kim A, et al. Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas. N Engl J Med. 2016;375:2550–60. Malhotra N, Levy JMS, Fiorillo L. Topical sirolimus as an effective treatment for a deep neurofibroma in a patient with neurofibromatosis type I. Pediatr Dermatol. 2019. https://doi.org/10.1111/pde.13782. NICE, National Institute for Health and Care Excellence, UK. Clinical Guideline CG164: Familial breast Cancer. Published date: June 2013. Available at: https://www.nice.org.uk/guidance/cg164 Accessed 29 Apr 2019 Ardern-Holmes S, Fisher G, North K. Neurofibromatosis type 2. J Child Neurol. 2017;32(1):9–22. https://doi.org/10.1177/0883073816666736. Asthagiri AR, Parry DM, Butman JA, Kim HJ, Tsilou ET, Zhuang Z, et al. Neurofibromatosis type 2. Lancet. 2009;373:1974–86. Evans DG, Birch JM, Ramsden RT. Paediatric presentation of type 2 neurofibromatosis. Arch Dis Child. 1999;81(6):496–9. Plotkin SR, O'Donnell CC, Curry WT, Bove CM, MacCollin M, Nunes FP. Spinal ependymomas in neurofibromatosis type 2: a retrospective analysis of 55 patients. J Neurosurg Spine. 2011;14(4):543–7. https://doi.org/10.3171/2010.11.SPINE10350. Asthagiri AR, Vasquez RA, Butman JA, Wu T, Morgan K, Brewer CC, et al. Mechanisms of hearing loss in neurofibromatosis type 2. PLoS One. 2012;7(9):e46132. https://doi.org/10.1371/journal.pone.0046132. Hexter A, Jones A, Joe H, Heap L, Smith MJ, Wallace AJ, et al. English specialist NF2 research group, Friedman JM, Evans DG. Clinical and molecular predictors of mortality in neurofibromatosis 2: a UK national analysis of 1192 patients. J Med Genet. 2015;52:699–705. Ferner RE, Shaw A, Evans DG, McAleer D, Halliday D, Parry A, et al. Longitudinal evaluation of quality of life in 288 patients with neurofibromatosis 2. J Neurol. 2014;261(5):963–9. https://doi.org/10.1007/s00415-014-7303-1. Baser ME, Friedman JM, Aeschliman D, Joe H, Wallace AJ, Ramsden RT, et al. Predictors of the risk of mortality in neurofibromatosis 2. Am J Hum Genet. 2002;71:715–23. Curto M, McClatchey A. Nf2/Merlin: a coordinator of receptor signalling and intercellular contact. Brit J Cancer. 2008;98:256–62. Halliday D, Emmanouil B, Pretorius P, MacKeith S, Painter S, Tomkins H, et al. Genetic severity score predicts clinical phenotype in NF2. J Med Genet. 2017;54:657–64. Smith MJ, Higgs JE, Bowers NL, Halliday D, Paterson J, Gillespie J, et al. Cranial meningiomas in 411 neurofibromatosis type 2 (NF2) patients with proven gene mutations: clear positional effect of mutations, but absence of female severity effect on age at onset. J Med Genet. 2011;48(4):261–5. https://doi.org/10.1136/jmg.2010.085241. Kontorinis G, Nichani J, Freeman SR, Rutherford SA, Mills S, King AT, et al. Progress of hearing loss in neurofibromatosis type 2: implications for future management. Eur Arch Otorhinolaryngol. 2015;272(11):3143–50. https://doi.org/10.1007/s00405-014-3317-7. Chung LK, Nguyen TP, Sheppard JP, Lagman C, Tenn S, Lee P, et al. A systematic review of radiosurgery versus surgery for neurofibromatosis type 2 vestibular schwannomas. World Neurosurg. 2018;109:47–58. Moffat DA, Lloyd SK, Macfarlane R, Mannion R, King A, Rutherford S, et al. Outcome of translabyrinthine surgery for vestibular schwannoma in neurofibromatosis type 2. Br J Neurosurg. 2013;27(4):446–53. Bernardeschi D, Peyre M, Collin M, Smail M, Sterkers O, Kalamarides M. Internal auditory canal decompression for hearing maintenance in neurofibromatosis type 2 patients. Neurosurgery. 2016;79(3):370–7. https://doi.org/10.1227/NEU.0000000000001125. King AT, Rutherford SA, Hammerbeck-Ward C, Lloyd SK, Freeman SR, Pathmanaban ON, et al. Malignant peripheral nerve sheath tumors are not a feature of neurofibromatosis type 2 in the unirradiated patient. Neurosurgery. 2018;83(1):38–42. https://doi.org/10.1093/neuros/nyx368. Mallory GW, Pollock BE, Foote RL, Carlson ML, Driscoll CL, Link MJ. Stereotactic radiosurgery for neurofibromatosis 2-associated vestibular schwannomas: toward dose optimization for tumor control and functional outcomes. Neurosurgery. 2014;74(3):292–300. Santa Maria PL, Shi Y, Gurgel RK, Corrales CE, Soltys SG, Santa Maria C, et al. Long-term hearing outcomes following stereotactic radiosurgery in vestibular schwannoma patients-a retrospective cohort study. Neurosurgery. 2018. https://doi.org/10.1093/neuros/nyy407. Plotkin SR, Stemmer-Rachamimov AO, Barker FG 2nd, Halpin C, Padera TP, Tyrrell A, et al. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med. 2009;361:358–67. Slusarz KM, Merker VL, Muzikansky A, Francis SA, Plotkin SR. Long-term toxicity of bevacizumab therapy in neurofibromatosis 2 patients. Cancer Chemother Pharmacol. 2014;73(6):1197–204. https://doi.org/10.1007/s00280-014-2456-2. • Morris KA, Golding JF, Axon PR, Afridi S, Blesing C, Ferner RE, et al. Bevacizumab in neurofibromatosis type 2 (NF2) related vestibular schwannomas: a nationally coordinated approach to delivery and prospective evaluation. Neurooncol Pract. 2016;3:281–9 Large, multicentre, prospective evaluation of efficacy and side-effects of bevacizumab in NF2 patients. Nunes FP, Merker VL, Jennings D, Caruso PA, di Tomaso E, Muzikansky A, et al. Bevacizumab treatment for meningiomas in NF2: a retrospective analysis of 15 patients. PLoS One. 2013;8(3):e59941. https://doi.org/10.1371/journal.pone.0059941. Peng KA, Lorenz MB, Otto SR, Brackmann DE, Wilkinson EP. Cochlear implantation and auditory brainstem implantation in neurofibromatosis type 2. Laryngoscope. 2018;128(9):2163–9. https://doi.org/10.1002/lary.27181. Harris F, Tysome JR, Donnelly N, Durie-Gair J, Crundwell G, Tam YC, et al. Cochlear implants in the management of hearing loss in neurofibromatosis type 2. Cochlear Implants Int. 2017;18(3):171–9. https://doi.org/10.1080/14670100.2017.1300723. Tolisano AM, Baumgart B, Whitson J, Kutz JW Jr. Cochlear implantation in patients with neurofibromatosis type 2. Otol Neurotol. 2019;40:e381–5. https://doi.org/10.1097/MAO.0000000000002165. Lu W, Pauly KB, Gold GE, Pauly JM, Hargreaves BA. SEMAC: slice encoding for metal artifact correction in MRI. Magn Reson Med. 2009;62(1):66–76. https://doi.org/10.1002/mrm.21967. Goutagny S, Kalamarides M. Meningiomas and neurofibromatosis. J Neuro-Oncol. 2010;99:341–7. Kalamarides M, Essayed W, Lejeune JP, Aboukais R, Sterkers O, Bernardeschi D, et al. Spinal ependymomas in NF2: a surgical disease? J Neuro-Oncol. 2018;136(3):605–11. https://doi.org/10.1007/s11060-017-2690-7. Morris KA, Afridi SK, Evans DG, Hensiek AE, McCabe MG, Kellett M, et al. The response of spinal cord ependymomas to bevacizumab in patients with neurofibromatosis type 2. J Neurosurg Spine. 2017;26:474–82. Farschtschi S, Merker VL, Wolf D, Schuhmann M, Blakeley J, Plotkin SR, et al. Bevacizumab treatment for symptomatic spinal ependymomas in neurofibromatosis type 2. Acta Neurol Scand. 2016;133(6):475–80. https://doi.org/10.1111/ane.12490. Feucht M, Griffiths B, Niemüller I, Haase W, Richard G, Mautner VF. Neurofibromatosis 2 leads to higher incidence of strabismological and neuro-ophthalmological disorders. Acta Ophthalmol. 2008;86(8):882–6. https://doi.org/10.1111/j.1600-0420.2007.01088.x. Bosch MM, Boltshauser E, Harpes P, Landau K. Ophthalmologic findings and long-term course in patients with neurofibromatosis type 2. Am J Ophthalmol. 2006;141(6):1068–77. Vakharia KT, Henstrom D, Plotkin SR, Cheney M, Hadlock TA. Facial reanimation of patients with neurofibromatosis type 2. Neurosurgery. 2012;70(2 Suppl Operative):237–43. https://doi.org/10.1227/NEU.0b013e31823a819f. Merker VL, Bergner AL, Vranceanu AM, Muzikansky A, Slattery W 3rd, Plotkin SR. Health-related quality of life of individuals with neurofibromatosis type 2: results from the NF2 natural history study. Otol Neurotol. 2016;37(5):574–9. https://doi.org/10.1097/MAO.0000000000001019. Kluwe L, Mautner V, Heinrich B, Dezube R, Jacoby LB, Friedrich RE, et al. Molecular study of frequency of mosaicism in neurofibromatosis 2 patients with bilateral vestibular schwannomas. J Med Genet. 2003;40:109–14. Karajannis MA, Legault G, Hagiwara M, Giancotti FG, Filatov A, Derman A, et al. Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas. Neuro-Oncology. 2014;16(2):292–7. https://doi.org/10.1093/neuonc/not150. Karajannis MA, Legault G, Hagiwara M, Ballas MS, Brown K, Nusbaum AO, et al. Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas. Neuro-Oncology. 2012;14(9):1163–70. https://doi.org/10.1093/neuonc/nos146. Osorio DS, Hu J, Mitchell C, Allen JC, Stanek J, Hagiwara M, et al. Effect of lapatinib on meningioma growth in adults with neurofibromatosis type 2. J Neuro-Oncol. 2018;139(3):749–55. https://doi.org/10.1007/s11060-018-2922-5.